RE:RE:RE:RE:RE:RE:Current capacity 1000 tests per dayokay, in reading through the documents on the JVs,
Joint arrangement 2 (JV2) will provide highly sensitive and specific serological assays for the detection and characterization of antibodies to the SARS-CoV-2 virus that is responsible for COVID-19. JV2 includes a jointly controlled venture (Immusafe Labs, Inc.) and jointly controlled operations. The Company acquired 50% of Immusafe Labs for $3,000. The Company is responsible to fund operating expenses, with prior notification of the planned expenditures, to bring the assay through approval.
But DKC still stay on ignore for calling me cupcake. I still think we get revenues from this activity. Time will tell.